Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sue, D.
Right arrow Articles by Wasserman, K
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sue, D.
Right arrow Articles by Wasserman, K

Chest, Vol 80, 537-542, Copyright © 1981 by American College of Chest Physicians

ARTICLES

beta-Adrenergic blockade with pindolol (LB-46) in mild to moderate asthma

DY Sue, JE Hansen and K Wasserman

Beta-adrenergic blockade may be hazardous in asthma and chronic obstructive lung disease. The beta-adrenergic antagonist pindolol (LB- 46) has been suggested to be more tolerable in such patients. We gave intravenously both 0.4 mg pindolol and placebo to 24 mild to moderate asthmatic subjects in remission. In 23 subjects who completed the study, there was no significant difference in pulmonary function between the pindolol and placebo trials either after drug administration or following exhausting exercise after drug administration, although a trend toward reduced pulmonary function after pindolol was seen. Significant differences (P less than 0.05) were found after inhaled isoproterenol when FEV1 and peak expiratory flow rates were compared. We conclude that in this group of mild to moderate asthmatic subjects, there was no adverse effect from pindolol even during exercise-induced bronchospasm. The response to isoproterenol may have been slightly impaired, but the clinical meaning of this is unclear.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter
Cardioselective {beta}-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis
Ann Intern Med, November 5, 2002; 137(9): 715 - 725.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American College of Chest Physicians.